Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Copeland

Showing results (81-90 of 82) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 82 results.
Blood Advances|December 31, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromesAmer M Zeidan, Isaac Boss, C L Beach, et al.
Plos Medicine|November 4, 2020
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trialsSamuel A Danziger, Mark McConnell, Jake Gockley, et al.
Pageof 9

Showing results (81-90 of 82) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 82 results.
Blood Advances|December 31, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromesAmer M Zeidan, Isaac Boss, C L Beach, et al.
Plos Medicine|November 4, 2020
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trialsSamuel A Danziger, Mark McConnell, Jake Gockley, et al.
Pageof 9